By Connor Hart
Shares of Medicus Pharma tumbled 39%, to $2.50, on the company's first day of trading Thursday.
The biotechnology and life-sciences pharmaceutical company on Wednesday said it would sell 970,000 units at about $4.13 apiece. Each unit consists of one common share of the company and one warrant to purchase one common share.
The company, which was seeking a valuation of $4 million, said it plans to use net proceeds from its IPO to fund a Phase 2 trial of its treatment of basal cell carcinoma, as well as to expand its trials to cover other non-melanoma skin diseases and for general corporate purposes.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
November 14, 2024 14:26 ET (19:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。